The British model Stephanie Dubois took the AstraZeneca COVID-19 vaccine in Papho, developed blood clots afterward and could not survive.
Dubois was announced dead on May 21, official confirmed.
The 39-year-old model who was based in Cyprus took her first dose of AstraZeneca more than two weeks prior, on May 6. She was reported to have experienced a “serious thrombotic episode” after the injection by Newsweek.
On the day of her initial shot, Dubois had shared on her social media account that her physical health was at odds.
“And now I feel horrendous … pizza and bed for me,” she wrote on Facebook.
Dubois was admitted to a hospital in Nicosia a week later on May 14, as she started to suffer from more severe symptoms.
“Woke up feeling fine and then within an hour I had full body shakes, all my joints seized and I was struggling to breathe and was cold to the bone with a persistent headache and dizziness,” the model updated her conditions online on the day she was hospitalized.
She later surmised the problem that was troubling her was the COVID-19 vaccine reaction. The negative test result suggested to her that it was something else.
“Maybe I’m having a prolonged reaction to my Covid jab last week, or maybe those side effects affected my immune system and I’ve caught something else in the process,” Dubois updated after she got a medical check.
Officials at her hospital said she was in good health before the COVID-19 vaccination.
Dubois’s condition got deteriorated, she suffered from a brain hemorrhage and then fell into a coma.
Charalambos Charilaou, a spokesperson of Cypriot health service, said the European Medicines Agency (EMA) would investigate her case.
Of all the AstraZeneca vaccinated citizens inside the country, there already are reports of two other cases of thrombosis incidents, according to Newsweek.
The reports have prompted the EMA to revise its vaccination guidance. The agency on May 21 added a recommendation for vaccine takers to avoid those of AstraZeneca if they “has had blood clots with low blood platelets (thrombosis with thrombocytopenia syndrome, TTS) after receiving the vaccine.”
The relationship between the COVID-19 vaccine doses developed by AstraZeneca and subsequent blood clots has been suggested in early April by European authorities.
The danger existed, but EMA on April 21 still reassured the public that the advantages of getting immunized were more critical than the potential threats as such occurrence was “rare.”
“The benefits of Vaxzevria (formerly COersVID-19 Vaccine AstraZeneca) outweigh its risks in adults of all age groups; however, every rare cases of blood clots with low blood platelets have occurred following vaccination… which are estimated to occur in one in 100,000 vaccinated people,” Newsweek reported, citing the EMA.